Skip to the content
  • Suomeksi
  • About Us
    • > Our role
    • > BoD and management
    • > Sustainability
  • Pharma Sector
    • > Feasibilities and inquiries
    • > Research archive
    • > References for post-licensure studies
  • Newsfeed
  • Contacts
  • Suomeksi

News
11.05.2023

Studying vaccines for CMV (cytomegalovirus)

clinical trials, clinical vaccine research, CMV, cytomegalovirus, vaccine trials

FVR – Finnish Vaccine Research has a team of specialists who have conducted two major clinical studies of CMV vaccines over several years, enrolling healthy women under 40 years of age. Our track-record of enrolling participants for these studies is good, despite screening criteria that limit the number of qualified participants, such as contact with young children, seronegativity or –positivity of the subject, or long commitment to study.

Finland offers an excellent setting for a successful study

  • educated and health-conscious people willing to participate in studies
  • generally a low drop-out rate once participants have committed to a study​
  • extensive network of research clinics
  • high quality register data and solid expertise available for phase 4 Real-World Evidence and pragmatic trials

Outi Laajalahti, ​Regional Lead Physician, explains.

Please accept the Marketing cookies to watch this video.

LOOKING FOR A CLINICAL TRIAL PARTNER?

PLEASE CONTACT info@fvr.fi FOR GENERAL INQUIRIES OR OUR BUSINESS UNIT HEADS DIRECTLY >>

  • About Us
    • Our role
    • BoD and management
    • Sustainability
  • Pharma Sector
    • Feasibilities and inquiries
    • Research archive
    • References for post-licensure studies
  • Newsfeed
  • Contacts

FVR - Finnish Vaccine Research
Peltokatu 26, 33100 Tampere, Finland
info@fvr.fi Business ID FI32566594

  • About cookies

© Copyrights 2022 FVR – Finnish Vaccine Research